Pascal Soriot, who runs drugs giant AstraZeneca, has slipped to third place in our annual survey, after being replaced by the ...

So Sir Pascal may seem an unlikely ally of Donald Trump, who as America’s president has slashed public spending on scientific research and seems determined to scrap the research grants of Ivy League ...

With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

AstraZeneca’s CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing ...

Today’s Forbes CFO newsletter focuses on Aradhana Sarin’s journey from treating patients to becoming what she calls a ...

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

AstraZeneca CFO Aradhana Sarin tells Yahoo Finance the company sees US innovation threatened by China, even as it commits $50 ...

President Donald Trump has given major pharmaceutical companies 60 days to slash prescription drug prices or face action.

Good morning. Thirty-three days. That’s how long it took from the time AstraZeneca CEO Pascal Soriot greeted Virginia Governor Glenn Youngkin in his London office to announcing a $4 billion ...

AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 ...

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on ...